@article{116,
  keywords = {Trypanosoma cruzi, protease inhibitors, leucyl-aminopeptidase, chemotherapy, bestatin-like peptidomimetics},
  author = {Gonzalez-Bacerio J and Arocha I and Aguado ME and Mendez Y and Marsiccobetre S and Izquierdo M and Rivera DG and Figarella K and Uzcategui NL},
  title = {KBE009: A Bestatin-Like Inhibitor of the Trypanosoma cruzi Acidic M17 Aminopeptidase with In Vitro Anti-Trypanosomal Activity},
  abstract = {Chagas disease, caused by the kinetoplastid parasite Trypanosoma cruzi, is a human tropical illness mainly present in Latin America. The therapies available against this disease are far from ideal. Proteases from pathogenic protozoan have been considered as good drug target candidates. T. cruzi acidic M17 leucyl-aminopeptidase (TcLAP) mediates the major parasite’s leucyl-aminopeptidase activity and is expressed in all parasite stages. Here, we report the inhibition of TcLAP (IC50 = 66.0 ± 13.5 µM) by the bestatin-like peptidomimetic KBE009. This molecule also inhibited the proliferation of T. cruzi epimastigotes in vitro (EC50 = 28.1 ± 1.9 µM) and showed selectivity for the parasite over human dermal fibroblasts (selectivity index: 4.9). Further insight into the specific effect of KBE009 on T. cruzi was provided by docking simulation using the crystal structure of TcLAP and a modeled human orthologous, hLAP3. The TcLAP-KBE009 complex is more stable than its hLAP3 counterpart. KBE009 adopted a better geometrical shape to fit into the active site of TcLAP than that of hLAP3. The drug-likeness and lead-likeness in silico parameters of KBE009 are satisfactory. Altogether, our results provide an initial insight into KBE009 as a promising starting point compound for the rational design of drugs through further optimization.},
  year = {2021},
  journal = {Life (Basel)},
  volume = {11},
  chapter = {1037},
  month = {10/2021},
  url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540442/},
  doi = {10.3390/life11101037},
}